Skip to main content
. Author manuscript; available in PMC: 2021 Oct 5.
Published in final edited form as: J Thromb Haemost. 2018 Apr 6;16(5):991–1002. doi: 10.1111/jth.13964

Fig. 5.

Fig. 5.

Anti-C5 antibody prolongs survival in the hemolytic-uremic syndrome (HUS) model in both Cpb2−/− and wild-type (WT) mice. Disease was induced by treatment with Stx2 and lipopolysaccharide (LPS) together as described in Methods and mice were followed until death (n = 11). Anti-C5 antibody was administered intraperitoneally at 3 h before disease induction and then every 24 h. Data were analyzed by the log rank method with the Bonferroni correction for multiple tests.